203 related articles for article (PubMed ID: 27527499)
1. Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014.
Matsumoto T; Tachimori H; Takano A; Tanibuchi Y; Funada D; Wada K
Psychiatry Clin Neurosci; 2016 Dec; 70(12):560-566. PubMed ID: 27527499
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics of dappou herb use--disorder patients at the drug dependence clinic: a comparison with methamphetamine use-disorder patients].
Tanibuchi Y; Matsumoto T; Kobayashi O; Wada K
Seishin Shinkeigaku Zasshi; 2013; 115(5):463-76. PubMed ID: 23855225
[TBL] [Abstract][Full Text] [Related]
3. [Current situation and clinical characteristics of sedative-related disorder patients in Japan: a comparison with methamphetamine-related disorder patients].
Matsumoto T; Ozaki S; Kobayashi O; Wada K
Seishin Shinkeigaku Zasshi; 2011; 113(12):1184-98. PubMed ID: 22352004
[TBL] [Abstract][Full Text] [Related]
4. [Current situation of substance abuse/dependence in psychiatric hospital settings].
Ozaki S
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2004 Feb; 39(1):35-40. PubMed ID: 15058092
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa.
Weich L; Pienaar W
Afr J Psychiatry (Johannesbg); 2009 Aug; 12(3):213-7. PubMed ID: 19750250
[TBL] [Abstract][Full Text] [Related]
6. The influence of tightening regulations on patients with new psychoactive substance-related disorders in Japan.
Tanibuchi Y; Matsumoto T; Funada D; Shimane T
Neuropsychopharmacol Rep; 2018 Dec; 38(4):189-196. PubMed ID: 30341809
[TBL] [Abstract][Full Text] [Related]
7. Changes of clinical symptoms in patients with new psychoactive substance (NPS)-related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction.
Funada D; Matsumoto T; Tanibuchi Y; Kawasoe Y; Sakakibara S; Naruse N; Ikeda S; Sunami T; Muto T; Cho T
Neuropsychopharmacol Rep; 2019 Jun; 39(2):119-129. PubMed ID: 30968601
[TBL] [Abstract][Full Text] [Related]
8. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
[TBL] [Abstract][Full Text] [Related]
9. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
Gillet C; Polard E; Mauduit N; Allain H
Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
[TBL] [Abstract][Full Text] [Related]
10. Drug abuse: a significant variable in schizophrenia research.
Boutros N; Bonnet K; Mak T
Biol Psychiatry; 1996 Jun; 39(12):1053-4. PubMed ID: 8780842
[No Abstract] [Full Text] [Related]
11. Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities.
Engelgardt P; Krzyżanowski M; Piotrowski P; Borkowska-Sztachańska M; Wasilewska A; Kowalkowski T
Int J Occup Med Environ Health; 2020 Mar; 33(2):125-136. PubMed ID: 31942874
[TBL] [Abstract][Full Text] [Related]
12. Managing misuse of novel psychoactive substances.
Solomon D; Grewal P; Taylor C; Solomon B
Nurs Times; 2014 May 28-Jun 3; 110(22):12-5. PubMed ID: 24984370
[TBL] [Abstract][Full Text] [Related]
13. New Psychoactive Substances (NPS) - the Hydra monster of recreational drugs.
Helander A; Bäckberg M
Clin Toxicol (Phila); 2017 Jan; 55(1):1-3. PubMed ID: 27549399
[No Abstract] [Full Text] [Related]
14. Substance abuse and onset of psychotic illness.
Kovasznay B; Bromet E; Schwartz JE; Ram R; Lavelle J; Brandon L
Hosp Community Psychiatry; 1993 Jun; 44(6):567-71. PubMed ID: 8514304
[TBL] [Abstract][Full Text] [Related]
15. Classical and novel psychoactive substances: rethinking drug misuse from an evolutionary psychiatric perspective.
St John-Smith P; McQueen D; Edwards L; Schifano F
Hum Psychopharmacol; 2013 Jul; 28(4):394-401. PubMed ID: 23881888
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of patients with designer-drug-related disorder in Japan: a comparison with patients with methamphetamine- and hypnotic/anxiolytic-related disorders.
Matsumoto T; Tachimori H; Tanibuchi Y; Takano A; Wada K
Psychiatry Clin Neurosci; 2014 May; 68(5):374-82. PubMed ID: 24405505
[TBL] [Abstract][Full Text] [Related]
17. Psychoactive drug abuse in older adults.
Simoni-Wastila L; Yang HK
Am J Geriatr Pharmacother; 2006 Dec; 4(4):380-94. PubMed ID: 17296542
[TBL] [Abstract][Full Text] [Related]
18. A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.
Anderson C; Morrell C; Marchevsky D
BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25948854
[TBL] [Abstract][Full Text] [Related]
19. Legislation targeting head shops selling new psychoactive substances and changes in drug-related psychiatric admissions: A national database study.
Smyth BP; Daly A; Elmusharaf K; McDonald C; Clarke M; Craig S; Cullen W
Early Interv Psychiatry; 2020 Feb; 14(1):53-60. PubMed ID: 30945460
[TBL] [Abstract][Full Text] [Related]
20. The rise of new psychoactive substance use in Australia.
Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J
Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
